Assay monitors response to monoclonal antibody therapy

Answers from the Lab

Risankizumab is a monoclonal antibody used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease. In this test-specific episode of the "Answers From the Lab" podcast, Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new risankizumab assay (Mayo ID: RISA) measures the drug's concentration in blood to guide optimal patient treatment.

"Therapeutic drug monitoring is routinely used to assess loss of response to therapy and proactively manage patients taking biologics. It has become standard of care in Crohn's disease," Dr. Willrich says. "But anyone taking risankizumab for any condition could be recommended to have this test."

The mass spectrometry-based test can quantify risankizumab from 1 to 100 micrograms per milliliter in serum samples. "That's expected to cover trough and peak concentrations expected in all the conditions that risankizumab is prescribed for," Dr. Willrich says. Additional testing for risankizumab antibodies is under development.

"If patients do not meet therapeutic drug concentrations, providers can decide to personalize the treatment regimen or discontinue the drug," Dr. Willrich says.

Listen to learn more about Mayo Clinic Laboratories' new risankizumab assay.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.


RISA   | Risankizumab, Serum

The latest

Barbara J. Toman

Barbara J. Toman is a Senior Communications Specialist at Mayo Clinic Laboratories. She is also the science writer for Mayo’s Neurosciences Update newsletter, which helps referring physicians to stay informed about Mayo’s treatment and research. Barbara has worked at Mayo Clinic since 2007. She enjoys international travel and cooking.